<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney stones in adults: Epidemiology and risk factors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney stones in adults: Epidemiology and risk factors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney stones in adults: Epidemiology and risk factors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary C Curhan, MD, ScD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Glenn M Preminger, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 04, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kidney stone disease (nephrolithiasis) is a common problem in primary care practice [<a href="#rid1">1,2</a>].</p><p>This topic will review the epidemiology of kidney stones and risk factors for stone formation in adults. Other aspects of kidney stones in adults are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7366.html" rel="external">"Kidney stones in adults: Diagnosis and acute management of suspected nephrolithiasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7377.html" rel="external">"Kidney stones in adults: Evaluation of the patient with established stone disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7373.html" rel="external">"Kidney stones in adults: Prevention of recurrent kidney stones"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7371.html" rel="external">"Kidney stones in adults: Surgical management of kidney and ureteral stones"</a>.)</p><p></p><p class="headingAnchor" id="H1589730051"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H926160909"><span class="h2">Prevalence and incidence</span><span class="headingEndMark"> — </span>Kidney stones are a common problem. A study based upon the National Health and Nutrition Examination Survey (NHANES) estimated that 19 percent of males and 9 percent of females will be diagnosed with a kidney stone by the age of 70 years [<a href="#rid1">1</a>].</p><p>In a report from the third NHANES, the population prevalence increased from 3.8 percent in this period from 1976 to 1980 to 5.2 percent in the period from 1988 to 1994 [<a href="#rid2">2</a>]. The prevalence increased in males and females, and in White patients and Black patients. Although one study suggested that the incidence rates since then may have leveled off [<a href="#rid3">3</a>], the 2007 to 2010 NHANES data found a continued increase in prevalence to 8.8 percent in the United States population [<a href="#rid1">1</a>]. Factors that may be contributing to this increase in stone prevalence include the increase in obesity, rising temperatures, and improvements and higher utilization of diagnostic imaging techniques:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> – The prevalence of ever having had a stone increases with age. According to data from NHANES cycles 2007 to 2016, the prevalence was 5.1 percent in males age 20 to 39 years, compared with 19.7 percent in males age 80 years and older [<a href="#rid4">4</a>]. Similarly, the prevalence was 5.8 percent in females age 20 to 39 years, compared with 10.6 percent in females age 80 years and older.</p><p></p><p class="bulletIndent1">Among males, the incidence (likelihood of having a first stone) is approximately 2 per 1000 per year in those under 40 years, increases to approximately 4 per 1000 per year in those 40 to 60 years, and then declines with age [<a href="#rid5">5</a>]. Among females, the incidence is approximately 2 per 1000 per year among those under 40 years and declines with age to approximately 1.5 per 1000 per year  (<a class="graphic graphic_figure graphicRef129762" href="/d/graphic/129762.html" rel="external">figure 1</a>). However, even an 80-year-old male or female may present with a first stone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex</strong> – Although the prevalence of a history of nephrolithiasis is similar among males and females below age 40 years, the overall prevalence of stone disease is approximately twice as high in males compared with females. Incidence rates are also similar in males and females below age 40 years, but above age 40 years the rates are higher in males than in females  (<a class="graphic graphic_figure graphicRef129762" href="/d/graphic/129762.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Race/ethnicity</strong> – Stone disease is most common in White patients who are not Hispanic, followed by White patients who are Hispanic, and is least common in Black patients and Asian patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Geography</strong> – In the United States, there is a north-south gradient and west-east gradient, with the higher prevalence of stone disease in the southeastern United States [<a href="#rid6">6</a>]. The reason for the higher prevalence is not clear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disability </strong>– In the United States, the prevalence of stone disease is higher among persons with functional disabilities than among those without disabilities (16 versus 9 percent, respectively) [<a href="#rid7">7</a>]. The reason for this higher prevalence is unclear but may be related to health care disparities in this patient population.</p><p></p><p class="headingAnchor" id="H2511558828"><span class="h2">Stone composition</span><span class="headingEndMark"> — </span>The frequency of different stone composition in adults is as follows  (<a class="graphic graphic_figure graphicRef129537" href="/d/graphic/129537.html" rel="external">figure 2</a>) [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium oxalate – 70 to 80 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium phosphate – 15 percent (apatite is the most common type of calcium phosphate crystal; brushite is much less common)</p><p class="bulletIndent1"><span class="glyph">●</span>Uric acid – 8 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Cystine – 1 to 2 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Struvite – 1 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Miscellaneous – &lt;1 percent</p><p></p><p class="headingAnchor" id="H1973403730"><span class="h2">Stone recurrence</span><span class="headingEndMark"> — </span>Despite how common nephrolithiasis is, high-quality and generalizable information on stone recurrence rates is scant.</p><p>The rate of stone recurrence is 10 to 30 percent at three to five years among patients with idiopathic calcium oxalate stones [<a href="#rid9">9-11</a>]. A higher recurrence rate of approximately 15 percent at 1 year, 35 to 40 percent at 5 years, and 50 percent at 10 years was found in another study and was higher in males than females [<a href="#rid12">12,13</a>] (see  <a class="medical medical_review" href="/d/html/7377.html" rel="external">"Kidney stones in adults: Evaluation of the patient with established stone disease"</a>). This variability is due, in part, to differences in sensitivity of different types of imaging modalities and different definitions of recurrence (eg, symptomatic versus radiologic change in stone size or stone number).</p><p>The overall stone recurrence rate depends on factors such as previous stone history (including composition) and type of treatment [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H3229484021"><span class="h1">MODIFIABLE RISK FACTORS</span></p><p class="headingAnchor" id="H1893068171"><span class="h2">Urinary factors</span><span class="headingEndMark"> — </span>Certain biochemical abnormalities of the urine composition have been associated with kidney stone formation. The degree to which these risk factors contribute to stone disease varies in different populations. In addition, the definitions of "abnormal" are somewhat arbitrary and may differ from study to study. Correction of these biochemical abnormalities may help to prevent recurrent stone formation. (See  <a class="medical medical_review" href="/d/html/7373.html" rel="external">"Kidney stones in adults: Prevention of recurrent kidney stones"</a>.)</p><p>Calcium phosphate and calcium oxalate stones share some risk factors such as low urine volume, high urine calcium, and low urine citrate [<a href="#rid14">14</a>]. However, there are also distinct risk factors for each type of stone. As an example, higher urine oxalate is a risk factor for calcium oxalate stones, while higher urine pH is a risk factor for calcium phosphate stones. Low urine volume and lower urine pH are risk factors for uric acid stones. Because the approach to stone prevention depends upon the composition of the stone, it is essential that every attempt is made to retrieve a passed or removed stone and to send it for analysis.</p><p>One study evaluated 1270 patients in Texas over a 15-year period for recurrent stone disease and reported their frequencies of urinary abnormalities [<a href="#rid15">15</a>]. Many patients had more than one risk factor:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypercalciuria – 61 percent, including some patients with primary hyperparathyroidism</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperuricosuric calcium stones – 36 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hypocitraturia – 28 percent idiopathic and 3.3 percent due to distal (type 1) renal tubular acidosis or chronic diarrhea</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperoxaluria – 8 percent, including enteric and primary forms and markedly increased oxalate intake</p><p class="bulletIndent1"><span class="glyph">●</span>Low urine volume (&lt;1 L/day) – 15 percent</p><p></p><p>Another report compared the frequency of these biochemical abnormalities in first-time stone formers and in individuals who had not formed a stone, and a substantial difference was noted only for urinary calcium and citrate excretion [<a href="#rid16">16</a>]. However, as noted above, dividing patients into "normal" and "abnormal" should be discouraged, as the risk is continuous.</p><p class="headingAnchor" id="H978499950"><span class="h3">High urine calcium</span><span class="headingEndMark"> — </span>An elevated urinary calcium excretion, with or without other risk factors, is observed in up to one-half of idiopathic calcium stone formers [<a href="#rid17">17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Hypercalciuria has been variably defined, and each definition has limitations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urinary calcium excretion greater than 250 mg/day (6.24 mmol/day) in females and greater than 300 mg/day (7.49 mmol/day) in males were the traditional definitions. However, there is no clear justification from the perspective of stone formation why a male is allowed to have more calcium in his urine than a female. The cutpoints used in published research studies and clinical laboratories vary substantially, with some using the same value for males and females, such as greater than 200 mg/day (4.99 mmol/day).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urinary calcium excretion greater than 4 mg/kg (0.1 mmol/kg) per day is another definition. The problem with this definition is that it allows heavier individuals to have more calcium in their urine than lighter individuals. While this may be appropriate from a calcium-balance standpoint, it does not make sense for stone formation. Since urine volume does not increase with weight gain, a "normal" urinary calcium excretion in a heavier person would result in a higher concentration of calcium in the urine (and a higher risk).</p><p></p><p class="bulletIndent1">An additional problem with dichotomous definitions is that the risk of stone formation rises with increasing urinary calcium excretion above 100 mg/day (2.5 mmol/day), not at some arbitrary threshold value. This was illustrated in a cross-sectional study of 3350 males and females, of whom 2237 had a history of nephrolithiasis  (<a class="graphic graphic_figure graphicRef132404" href="/d/graphic/132404.html" rel="external">figure 3</a>) [<a href="#rid17">17</a>]. Compared with a 24-hour urinary calcium excretion below 100 mg, the relative risk of being a stone former in older females was 1.52 for a urinary calcium of 150 to 199 mg/day (3.74 to 4.97 mmol/day), 1.84 for a urinary calcium of 200 to 249 mg/day (4.99 to 6.23 mmol/day), and 1.93 for a urinary calcium of 250 to 299 mg/day (6.24 to 7.48 mmol/day). The relative risk increased further at clearly hypercalciuric levels: 2.68 and 4.94 at urinary calcium of 300 to 349 mg/day (7.49 to 8.72 mmol/day) and greater than 350 mg/day (8.73 mmol/day), respectively. Similar results were found in males and younger females. The relation to risk appears to be continuous. Thus, the use of the term "hypercalciuria" is not ideal, because there is no clear threshold below which the risk is low and above which the risk is high.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – Possible reasons for higher urine calcium in calcium stone formers include primary hyperparathyroidism, chronic acidemia from distal renal tubular acidosis, and very high levels of calcium intake (typically supplemental calcium) [<a href="#rid18">18,19</a>]. However, most calcium stone formers with higher urine calcium do not have either of these disorders or have excessive calcium intake. (See  <a class="medical medical_review" href="/d/html/2369.html" rel="external">"Nephrolithiasis in renal tubular acidosis"</a>.)</p><p></p><p class="bulletIndent1">High urine calcium excretion without an identifiable cause is often referred to as idiopathic hypercalciuria. Conceptually, it is useful to consider three contributions to higher urinary calcium excretion [<a href="#rid20">20,21</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased intestinal absorption ("absorptive hypercalciuria") in which there is an increase in intestinal calcium absorption [<a href="#rid22">22,23</a>]. However, dietary calcium intake typically should not be restricted unless it is &gt;1000 mg/day. (See <a class="local">'Calcium'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased bone resorption ("resorptive hypercalciuria") in which the source of the excess calcium may be bone.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased renal losses ("renal hypercalciuria") in which there is a defect in renal tubular calcium reabsorption.</p><p></p><p class="bulletIndent1">The clinical significance of this classification is uncertain. Most individuals with higher urine calcium exhibit more than one abnormality and may change categories over time. Thus, it is not necessary for clinical purposes to perform calcium-loading or calcium-restriction tests.</p><p></p><p class="bulletIndent1">It has been suggested that idiopathic hypercalciuria is transmitted as an autosomal dominant trait. Reports have suggested certain gene defects [<a href="#rid24">24,25</a>], but others have been unsuccessful in identifying a locus. This may be due to the likely substantial heterogeneity of this disorder [<a href="#rid26">26,27</a>]. One genome-wide association study involving 6462 adults found a single-nucleotide polymorphism (SNP; rs17216707 on chromosome 20) significantly associated with 24-hour urine calcium excretion [<a href="#rid28">28</a>]. This SNP is located near <em>CYP24A1</em>, the gene that encodes the enzyme that inactivates 1,25-dihydroxyvitamin D.</p><p></p><p class="bulletIndent1">Idiopathic hypercalciuria may be associated with a slightly higher plasma concentration of calcitriol (1,25-dihydroxyvitamin D3) [<a href="#rid29">29,30</a>], although the values are rarely above the upper limit of the reference range. Higher calcitriol levels can enhance calcium excretion both by increasing intestinal calcium absorption (absorptive hypercalciuria) and by promoting bone resorption (resorptive hypercalciuria) [<a href="#rid31">31</a>]. The latter effect has important clinical implications since lowering calcium intake may not dramatically reduce urine calcium excretion and may result in negative calcium balance, leading to calcium being removed from bone. If prolonged, the negative calcium balance can lead to osteopenia [<a href="#rid29">29,32-35</a>]. This may be particularly important since some untreated patients with hypercalciuria already have diminished bone density, due possibly to increased bone resorption [<a href="#rid29">29</a>]. However, excessive supplemental calcium does not "drive" calcium into the bones and may instead lead to higher urine calcium excretion (thereby increasing stone risk). Thus, careful consideration of the risks and benefits of supplemental calcium intake is essential.</p><p></p><p class="bulletIndent1">In addition, while modest intake of supplemental vitamin D does not appear to increase the risk of stone formation in most individuals [<a href="#rid36">36</a>], excessive intake could increase the risk, particularly in combination with calcium supplements [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">The factors responsible for the higher calcitriol levels in some patients with idiopathic hypercalciuria are not well understood. It has been proposed that a urinary phosphate leak might be the primary defect [<a href="#rid38">38</a>], leading to a mild reduction in the plasma phosphate concentration that would then stimulate the synthesis of calcitriol.</p><p></p><p class="headingAnchor" id="H2677136516"><span class="h3">High urine oxalate</span><span class="headingEndMark"> — </span>The risk of calcium oxalate stone formation increases as urine oxalate excretion increases [<a href="#rid17">17</a>]. It was believed that a small increase in oxalate excretion represented a relatively large percentage change and, therefore, was more likely to promote calcium oxalate precipitation to a greater degree than a similar absolute increase in calcium excretion [<a href="#rid39">39,40</a>], but this has been questioned. The reported frequency of hyperoxaluria varies widely depending upon the sex and number of previous stones in the population studied  (<a class="graphic graphic_table graphicRef78303" href="/d/graphic/78303.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – The widely used definition of normal urinary oxalate excretion is less than 45 mg/day (0.5 mmol/day), generally less than 20 percent that of calcium [<a href="#rid41">41</a>]. However, similar limitations of the chosen "normal" cutpoint also apply to oxalate. In fact, the risk of stone formation begins to increase significantly at urinary oxalate excretion above 25 mg/day, well within the "normal" range [<a href="#rid17">17</a>]. Thus, the risk of stone formation increases with increasing urine oxalate, even if the value is within the "normal" range.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – The relative contribution of endogenous and exogenous oxalate to urine oxalate excretion remains uncertain [<a href="#rid40">40,42</a>]. Although there is general agreement that increasing dietary oxalate increases urinary oxalate excretion, the amount of the increase varies substantially by the type of food (not just the oxalate content of the food); the overall impact of dietary oxalate on stone risk appears to be relatively small [<a href="#rid40">40,43</a>], but it is substantially influenced by concomitant calcium intake, with the risk being higher in those with lower calcium intake. It also varies because some individuals are more sensitive to dietary oxalate intake due to differences in oxalate absorption.</p><p></p><p class="bulletIndent1">Endogenous oxalate is primarily derived from the metabolism of glycine and ascorbic acid [<a href="#rid41">41</a>]. The actual contribution of dietary oxalate to urinary oxalate excretion has been difficult to ascertain, given incomplete information on the oxalate content and bioavailability in many foods. Dietary oxalate may have a more prominent effect in individuals with idiopathic calcium oxalate nephrolithiasis; these individuals seem to have a higher rate of oxalate absorption (and urinary excretion) than control patients given the same standard diet and amount of exogenous oxalate [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/d/html/6141.html" rel="external">"Primary hyperoxaluria"</a>.)</p><p></p><p class="bulletIndent1">The importance of intestinal oxalate absorption is supported by observations regarding the effect of dietary calcium. Dietary calcium can decrease oxalate absorption in the gut by the formation of insoluble calcium oxalate salts in the intestinal lumen. When less calcium is available in the intestinal lumen to bind oxalate, oxalate absorption, and therefore urinary oxalate excretion, increases. Relatively common settings in which this occurs include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With a low-calcium diet, which is generally not recommended for idiopathic calcium stones [<a href="#rid11">11</a>] (see <a class="local">'Calcium'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With increased intestinal calcium absorption, as may be seen in individuals with higher urine calcium</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Malabsorption syndromes, as with small bowel disease (eg, Crohn disease), surgical bowel resection or diversion, including jejunoileal bypass for obesity (bariatric surgery), or cystic fibrosis [<a href="#rid45">45-52</a>]</p><p></p><p class="bulletIndent1">This last situation leads to the malabsorption of fatty acids and bile salts and is called enteric hyperoxaluria. The increase in oxalate absorption and subsequent excretion is due both to binding of free calcium to fatty acids in the intestinal lumen and to increased colonic permeability to small molecules such as oxalate induced by exposure of the colon to nonabsorbed bile salts [<a href="#rid53">53-56</a>].</p><p></p><p class="bulletIndent1">The rate of hyperoxaluric stone formation is higher in patients who have undergone some types of bariatric surgery. This is discussed in more detail elsewhere in this topic. (See <a class="local">'Medical conditions'</a> below.)</p><p></p><p class="bulletIndent1">Alterations in gastrointestinal flora, such as may be seen with prolonged administration of antibiotics (common in disorders such as cystic fibrosis) can lead to decreased degradation of oxalate and, thus, increase the risk of hyperoxaluria [<a href="#rid57">57-59</a>]. One possibility is the loss of the bacterium <em>Oxalobacter formigenes</em>, or other bacteria that degrade oxalate and promote enteric oxalate secretion (thus reducing urinary oxalate excretion) [<a href="#rid60">60-64</a>].</p><p></p><p class="bulletIndent1">In addition, it has been proposed that mild hyperoxaluria may be due to a genetic abnormality (with autosomal dominant inheritance) characterized by increased activity of a chloride/oxalate anion exchanger (similar to the band 3 protein, chloride/bicarbonate exchanger in the red cell). This abnormality has been demonstrated in red cells and is associated with increased fractional oxalate excretion, suggesting that it is also present in the renal tubules [<a href="#rid39">39</a>]. Another possibility suggested by an experimental model is a defect in oxalate secretion into the intestinal lumen [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">Higher oxalate production may contribute to the risk of calcium oxalate stone formation, but the mechanisms that control endogenous oxalate production are unclear. Higher oxalate production is a likely contributor to the higher risk of stone disease in males compared with females. Dramatically increased oxalate production can occur in the setting of high-dose <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> therapy and primary hyperoxaluria, a rare disorder in which enzyme deficiencies lead to overproduction of oxalate from glyoxylate. (See <a class="local">'Vitamin C'</a> below and  <a class="medical medical_review" href="/d/html/6141.html" rel="external">"Primary hyperoxaluria"</a>.)</p><p></p><p class="headingAnchor" id="H937328487"><span class="h3">Low urine citrate</span><span class="headingEndMark"> — </span>A decrease in excretion of urinary inhibitors of crystal formation is another mechanism that can promote the development of kidney stones [<a href="#rid66">66-70</a>]. One substance thought to be a principal inhibitor of calcium stone formation is citrate. Low urine citrate can occur in isolation in stone formers or in combination with other urinary abnormalities including high urine calcium and high urine oxalate:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Hypocitraturia has been defined as citrate excretion below 320 mg/day. However, as with all urinary factors, this definition is somewhat arbitrary [<a href="#rid17">17</a>], and the association with risk of stone formation is continuous [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – Citrate acts in the tubular lumen by combining with calcium to form a nondissociable but soluble complex. As a result, there is less free calcium available to combine with oxalate. In addition, citrate also appears to inhibit the important process of crystal agglomeration, in which individual calcium oxalate crystals combine to form a stone [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1">One major factor that can limit citrate excretion by enhancing proximal reabsorption is chronic metabolic acidosis induced by chronic diarrhea, renal tubular acidosis (complete or incomplete), the administration of carbonic anhydrase inhibitors (including antiseizure medications such as <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> and <a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">zonisamide</a>), or ureteral diversion. (See  <a class="medical medical_review" href="/d/html/2369.html" rel="external">"Nephrolithiasis in renal tubular acidosis"</a> and <a class="local">'Medications'</a> below.)</p><p></p><p class="bulletIndent1">A fall in citrate excretion can also be induced by a high animal protein diet [<a href="#rid72">72</a>], a setting in which acid generation is enhanced. High-protein diets, while still popular for weight loss, can have substantial adverse effects on urine citrate. Similarly, a diet low in fruits and vegetables may result in low urinary potassium, which is correlated with urine citrate excretion [<a href="#rid73">73</a>]. (See <a class="local">'Protein'</a> below and <a class="local">'Potassium'</a> below.)</p><p></p><p class="bulletIndent1">In incomplete distal (type 1) renal tubular acidosis, a disorder that might actually represent a primary proximal tubular defect, hypocitraturia might occur in the absence of overt metabolic acidosis [<a href="#rid74">74</a>]. There are no studies establishing the frequency of incomplete distal (type 1) renal tubular acidosis in this setting. This disorder should be suspected if the urine pH is persistently above 5.3 along with low or low-normal serum total carbon dioxide; the diagnosis is confirmed by the lack of acidification of the urine after an ammonium chloride load. However, ammonium chloride loading is rarely used in the evaluation of stone formers, as patients may be treated with alkali regardless of the results of this test. (See  <a class="medical medical_review" href="/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis"</a>.)</p><p></p><p class="headingAnchor" id="H2139143303"><span class="h3">High urine uric acid</span><span class="headingEndMark"> — </span>Hyperuricosuria has been traditionally, although arbitrarily, defined as a 24-hour urine uric acid excretion of more than 750 mg (4.5 mmol) in females or more than 800 mg (4.8 mmol) in males.</p><p></p><p>In the past, a higher urine uric acid had been considered to promote calcium oxalate stone formation. One proposed mechanism was that uric acid crystals formed a nidus for subsequent calcium oxalate precipitation [<a href="#rid75">75</a>]. Support for the role of hyperuricosuria came from a randomized, controlled trial in which <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a> significantly reduced the likelihood of calcium oxalate stone recurrence in calcium stone formers with hyperuricosuria but "normal" urinary calcium excretion (0.12 versus 0.26 calculus events per year with placebo) [<a href="#rid76">76</a>].</p><p>However, the role of uric acid in calcium oxalate stone formation remains unproven. In the cross-sectional observational study of 3350 males and females (2237 with a history of nephrolithiasis), mean 24-hour uric acid excretion did not differ between stone formers and controls [<a href="#rid17">17</a>]. Multivariate adjustment for other urinary factors revealed a significant, independent, <strong>inverse</strong> association between uric acid excretion and the likelihood of being a stone former in males and marginally in younger females. By contrast, the expected associations with volume, hypercalciuria, hyperoxaluria, and hypocitraturia were found.</p><p>These observations suggest that high urine uric acid may not be a risk factor for calcium stone formation and that <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a> may lower the risk of stone formation through a mechanism other than lowering uric acid excretion.</p><p>Higher urine uric acid is also a risk factor for uric acid stone formation, although the major risk factor for uric acid stones is a persistently lower urine pH. (See <a class="local">'Urine pH'</a> below.)</p><p class="headingAnchor" id="H3183379242"><span class="h3">Low urine volume</span><span class="headingEndMark"> — </span>Nephrolithiasis is a disease driven by the urinary concentration of lithogenic factors. Thus, higher urine volume has been consistently found to be associated with a lower risk of kidney stone formation [<a href="#rid17">17</a>]. There is no generally accepted definition of low urine volume; as with other urinary factors, the risk is continuous, but an accepted goal is at least 2.5 liters of urine daily [<a href="#rid77">77</a>].</p><p>The main determinant of urine volume is total fluid intake, and, therefore, it is not surprising that higher fluid intake has been consistently found to be one of the other strongest protective factors against kidney stone formation [<a href="#rid78">78</a>]. (See <a class="local">'Fluid intake'</a> below.)</p><p class="headingAnchor" id="H3318058527"><span class="h3">Urine pH</span><span class="headingEndMark"> — </span>The urine pH contributes to the likelihood of formation of certain types of stones. An acid urine (typical for most individuals) favors uric acid precipitation when the pH is consistently 5.5 or less. An alkaline urine (as may be seen with urinary tract infections and renal tubular acidosis but also in individuals with higher dietary alkali intake) promotes calcium phosphate stone formation, typically when the pH is 6.5 or higher. Calcium oxalate stones are not pH dependent in the physiologic range.</p><p class="headingAnchor" id="H1744825636"><span class="h2">Dietary factors</span><span class="headingEndMark"> — </span>Dietary factors can play an important role in promoting stone formation, primarily by affecting the composition of the urine. Studies over the past few decades suggest that the importance of specific dietary risk factors varies by age and sex.</p><p>A longitudinal study of three cohorts involving over 192,000 participants estimated the population attributable fraction of incident kidney stones that could be prevented by optimizing five dietary and lifestyle factors to minimize stone risk [<a href="#rid79">79</a>]. The factors were body mass index (BMI), fluid intake, Dietary Approaches to Stop Hypertension (DASH)-style diet, dietary calcium intake, and sugar-sweetened beverage intake. These five modifiable risk factors accounted for more than 50 percent of incident kidney stones. If a causal relationship exists, these findings suggest that preventive measures aimed at reducing those factors could substantially decrease the burden of kidney stones.</p><p class="headingAnchor" id="H974260789"><span class="h3">Fluid intake</span><span class="headingEndMark"> — </span>A lower fluid intake will lead to a lower urine output, thereby promoting stone formation by increasing the concentration of lithogenic substances such as calcium and oxalate (even though the total amount of excretion of these lithogenic factors is not affected). In one report, for example, patients who had a first kidney stone had a baseline daily urine output that was 250 to 350 mL less than controls [<a href="#rid78">78</a>]. A related concern arises among individuals who work in a very hot environment (with increased insensible losses), in whom the risk of nephrolithiasis is markedly increased without adequate fluid intake [<a href="#rid80">80</a>]. (See <a class="local">'Other factors'</a> below.)</p><p>The importance of fluid intake on the risk of incident stone formation has been illustrated by data from several cohort studies [<a href="#rid81">81-84</a>]. In these reports of over 200,000 males and females, there was a 30 percent lower risk of developing symptomatic kidney stones in participants in the highest quintile of fluid intake compared with those in the lowest quintile.</p><p>In addition to lower fluid intake as a risk factor for incident stone disease, increasing fluid intake can lead to a reduction in recurrent stone formation. (See  <a class="medical medical_review" href="/d/html/7373.html" rel="external">"Kidney stones in adults: Prevention of recurrent kidney stones", section on 'Fluid intake'</a>.)</p><p class="headingAnchor" id="H2763018344"><span class="h4">Type of fluid</span><span class="headingEndMark"> — </span>The type of fluid taken in may also be important, although data are sometimes conflicting regarding the effect on urine composition and stone risk. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Data from three large, prospective cohort studies suggest that sugar-sweetened beverages (including both cola and non-cola beverages) are associated with an increased risk of developing kidney stones [<a href="#rid85">85</a>]. Compared with nonusers of these beverages, the relative risk was 23 percent higher among those drinking one or more sugar-sweetened colas per day and 33 percent higher among those consuming one or more sugar-sweetened non-colas per day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coffee and tea have, in the past, been considered to have a high oxalate content. However, some measurements have not found these beverages to be high in oxalate. In fact, consumption of large amounts of tea appears to have a negligible impact on urinary oxalate excretion [<a href="#rid86">86</a>]. In prospective studies, higher tea and coffee (including decaffeinated coffee) consumption was associated with a lower risk of stone formation [<a href="#rid85">85</a>]. A study of twins in the United States also found that coffee and perhaps tea were relatively protective [<a href="#rid87">87,88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alcoholic beverages had been purported to increase the risk of stones. However, prospective studies found that beer and wine were associated with a lower risk of stone formation [<a href="#rid85">85,89</a>], possibly due to inhibition of antidiuretic hormone (ADH) release [<a href="#rid90">90,91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Orange juice (which contains both potassium and citrate) was associated with a lower calculated risk of crystal formation (possibly due in part to increased urinary citrate excretion) [<a href="#rid92">92-94</a>], and large cohort studies found that orange juice was independently associated with a reduced likelihood of stone formation [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cranberry juice, advocated as prophylaxis against recurrent urinary tract infections, has been variably reported to increase and decrease urinary saturation of calcium oxalate and/or urine pH [<a href="#rid95">95-97</a>]. There have been no studies correlating consumption of cranberry juice to actual stone formation.</p><p></p><p class="headingAnchor" id="H21371866"><span class="h3">Calcium</span><span class="headingEndMark"> — </span>Ingested calcium is absorbed in the intestines and later excreted in the urine; the proportion absorbed is higher in patients with hypercalciuria [<a href="#rid98">98</a>]. Although this suggests that a diet higher in calcium might promote stone disease, the opposite effect is seen, as the risk of stone formation appears to be reduced in both males and females [<a href="#rid11">11,81-84</a>]. By contrast, calcium supplements may slightly increase the propensity to form stones, at least in older females [<a href="#rid37">37,84</a>].</p><p>In the Nurses' Health Study, a higher dietary calcium intake was associated with a lower incidence of stone disease (multivariate relative risk 0.65 for highest versus lowest quintile of calcium intake) while calcium supplements were associated with a small increase in risk (relative risk 1.2 in supplement users compared with nonusers) [<a href="#rid83">83</a>]. The impact of dietary calcium may vary by age. This was suggested in a report from a cohort of males that also found an association between increased dietary calcium and decreased stone formation in males under the age of 60 years but not in older males [<a href="#rid82">82</a>].</p><p>A possible explanation for this phenomenon of contrasting risks depending upon the source of calcium (dietary versus supplements) is related to the timing of calcium intake, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Dietary calcium sources may be ingested with foods containing oxalate, binding dietary oxalate in the gut, leading to decreased oxalate absorption and excretion. The fall in oxalate excretion exceeds the rise in calcium excretion; the net effect is a reduction in the relative supersaturation of the urine with respect to calcium oxalate [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Calcium supplements are often taken in the morning or before bedtime and not with meals; thus, due to this timing, they would not be expected to effectively bind dietary oxalate. This would lead to both maintaining oxalate excretion and, by keeping calcium free in the intestinal lumen, increasing calcium absorption and urinary excretion.</p><p></p><p>It is also possible that there may be other inhibitory factors in dairy products, which are the major source of dietary calcium (though the risk was also lower with higher dietary calcium intake from nondairy sources) [<a href="#rid99">99</a>].</p><p>Some investigators have attempted to categorize individuals based upon their pattern of calcium absorption and excretion. In patients classified as having absorptive hypercalciuria, dietary calcium restriction reduced urinary calcium. However, since there would not be a concomitant change in urinary oxalate excretion, there would be a lesser reduction in the relative supersaturation of calcium oxalate, unless perhaps dietary oxalate were also restricted [<a href="#rid100">100</a>]. However, evidence is lacking that restriction of dietary calcium reduces the rate of stone formation in these patients, and there is substantial evidence that reducing dietary calcium intake could be harmful; thus, a low-calcium diet is not recommended.</p><p>An understanding of all of these factors is essential for the appropriate evaluation and treatment of patients with calcium stone disease. (See  <a class="medical medical_review" href="/d/html/7377.html" rel="external">"Kidney stones in adults: Evaluation of the patient with established stone disease"</a> and  <a class="medical medical_review" href="/d/html/7373.html" rel="external">"Kidney stones in adults: Prevention of recurrent kidney stones"</a>.)</p><p class="headingAnchor" id="H3416184974"><span class="h3">Oxalate</span><span class="headingEndMark"> — </span>Oxalate is found in many foods, typically in small amounts. Oxalate is also generated from the metabolism of glycine, hydroxyproline, and <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> (ascorbic acid). Oxalate absorbed from dietary sources or produced from endogenous metabolism is eventually excreted in the urine. There is continued debate regarding the relative contribution of dietary and endogenously derived oxalate on urinary oxalate; it has been estimated that 10 to 50 percent of urinary oxalate is derived from dietary oxalate [<a href="#rid40">40,101</a>].</p><p>Difficulties in measuring the oxalate content of individual foods has previously led to unreliable information. Reliable assays now exist for direct determination of oxalate in foods [<a href="#rid40">40,102,103</a>]. There is currently a list of more than 200 foods analyzed with more modern methods, which can be downloaded from the following <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hsph.harvard.edu%2Fnutrition-questionnaire-service-center%2F&amp;token=RMl7U%2FCatO9A86umCdxqsUsD%2Fh6LKdg46%2BQJEvN7baqBAlTo%2BC9da5qfQKSn85mN%2F1jrSQKpqSQOXiBUBIpsCPOvua6YJJFu7u4LS03L%2FfE%3D&amp;TOPIC_ID=7375" target="_blank">website</a>. The lack of information on food oxalate content has previously hindered efforts to examine the impact of dietary oxalate on stone formation.</p><p>To examine the relation between stone risk and oxalate intake, a prospective study was performed based upon food frequency questionnaires of three large cohorts: the Health Professionals Follow-up Study and the Nurse's Health Studies I and II [<a href="#rid43">43</a>]. When individuals in the highest quintile for dietary oxalate intake were compared with the lowest quintile, there was a mild increase in the risk of stones for males (relative risk of 1.22, 95% CI 1.03-1.45) and for older females (relative risk of 1.21, 95% CI 1.01-1.44). This risk was higher in males with a lower dietary intake of calcium. In addition, eight or more servings of spinach per month (which accounted for &gt;40 percent of oxalate intake) compared with fewer than one serving per month was associated with a similar increase in stone risk for males and older females. By contrast, dietary oxalate and spinach intake were not associated with an increased risk in younger females. Thus, dietary oxalate intake appears to be a modest risk factor for incident kidney stones in the general population, but this risk likely varies by individual. The urine oxalate level is a very strong predictor of stone risk. Individuals who form calcium oxalate stones may absorb a higher proportion of dietary oxalate.</p><p>Dietary intervention studies have also demonstrated that higher oxalate intake increases urinary oxalate and presumably increases the risk of stone formation [<a href="#rid104">104</a>]. However, other factors also need to be considered, such as higher intake of calcium and magnesium, which may reduce the absorption of dietary oxalate [<a href="#rid105">105,106</a>]. (See <a class="local">'High urine oxalate'</a> above.)</p><p>Nevertheless, because the risk of stone formation increases with increasing urinary oxalate, a lower intake of dietary oxalate and <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> seems prudent [<a href="#rid17">17,101</a>]. The challenge remains how to choose a low-oxalate diet without inappropriately restricting intake of fruits and vegetables. Aggressive restriction of dietary oxalate is not practical. Follow-up 24-hour urine oxalate measurements should be used to determine if the dietary oxalate restriction is beneficial; if not, then it should be discontinued.</p><p class="headingAnchor" id="H3689921890"><span class="h3">Potassium</span><span class="headingEndMark"> — </span>A higher dietary potassium intake was associated with a substantially reduced risk of incident stone formation in males and females [<a href="#rid107">107</a>]. One possible explanation is that higher potassium intake may reduce the risk of stone formation by reducing urinary calcium excretion [<a href="#rid108">108</a>].</p><p>Another mechanism is that higher potassium intake may increase urinary citrate excretion (since potassium-rich foods tend to have a high alkali content) thereby increasing the inhibitory properties of urine. Foods that are rich in potassium include fruits and vegetables. Although some have recommended a reduction in the intake of certain fruits and vegetables with the hope this would reduce oxalate intake and excretion, other studies found a slight protective effect of fruit ingestion [<a href="#rid73">73,87</a>]. Overall, given that dietary potassium is associated with a lower risk and fruits and vegetables are a major source of dietary potassium, it seems that there is evidence to encourage intake of fruits and vegetables (while avoiding those that are very high in oxalate such as spinach, rhubarb, and potatoes).</p><p class="headingAnchor" id="H2689407973"><span class="h3">Sodium</span><span class="headingEndMark"> — </span>A high sodium intake will enhance the excretion of calcium, a relation that has been thought to be due in part to the reabsorption of calcium passively following that of sodium and water in the proximal tubule [<a href="#rid109">109</a>]. Thus, the decrease in proximal sodium reabsorption induced by volume expansion will lead to a parallel reduction in calcium transport and increased calcium excretion [<a href="#rid110">110,111</a>]. In one study of stone formers with idiopathic hypercalciuria, for example, increasing sodium intake from 80 to 200 mEq/day led to nearly a 40 percent rise in calcium excretion (from 278 to 384 mg/day [7 to 9.5 mmol/day]) [<a href="#rid110">110</a>]. This increase in calcium excretion may result in negative calcium balance, which would promote the development of osteopenia [<a href="#rid32">32,33</a>].</p><p>A high-sodium diet may also produce an undesirable reduction in citrate excretion via an uncertain mechanism [<a href="#rid111">111</a>]. In addition, the anion accompanying sodium appears to be a determinant of the effect on calcium excretion. In particular, chloride seems to be required for the calciuresis to occur [<a href="#rid111">111</a>]. How chloride acts in this setting is not clear.</p><p>The clinical magnitude of these effects on stone formation is not clear. The Nurses' Health Study noted a relative risk of 1.30 for symptomatic stones in females in the highest quintile of sodium intake compared with those in the lowest quintile [<a href="#rid83">83</a>]. No association was seen in males or younger females [<a href="#rid81">81,82,84</a>], although the lack of an association may be due to the difficulty in accurately assessing sodium intake by questionnaires. In the study of over 3300 individuals with 24-hour urine collections, urine sodium excretion was not independently associated with likelihood of being a stone former [<a href="#rid17">17</a>], but these analyses were adjusted for calcium and citrate (the potential factors through which sodium may act). In the Women's Health Initiative, the risk of stone formation was 61 percent higher among females in the highest quintile of sodium intake compared with the lowest quintile [<a href="#rid112">112</a>].</p><p class="headingAnchor" id="H4209655551"><span class="h3">Protein</span><span class="headingEndMark"> — </span>Different types of dietary protein may have different effects on the risk of kidney stones. As an example, a high animal protein intake has been associated with a slightly higher incidence of stone disease, at least in males; by contrast, vegetable protein intake has not been associated with stone risk [<a href="#rid81">81,82,107</a>]. In addition, the risk of stones associated with animal protein intake may vary depending upon whether the source of the animal protein is dairy or nondairy. In one study, higher nondairy animal protein intake was associated with a modest but nonsignificant increase in stone risk, whereas higher dairy protein intake in young females was associated with a lower risk of stone disease [<a href="#rid107">107</a>].</p><p>Higher animal protein intake (both nondairy and dairy) is associated with higher urine calcium excretion [<a href="#rid107">107,113-116</a>]. In addition, higher nondairy, animal protein intake is associated with lower urine citrate, whereas higher dairy protein intake is associated with higher urine citrate excretion and lower urine oxalate excretion [<a href="#rid107">107</a>]. Vegetable protein has a much lesser effect on calcium, uric acid, and citrate excretion since it has a lower sulfur content and therefore generates less acid [<a href="#rid88">88,115,117</a>].</p><p>There are several factors that may explain the higher urine calcium excretion resulting from higher animal protein intake:</p><p class="bulletIndent1"><span class="glyph">●</span>Long term, a high-protein diet may lead to higher urine calcium excretion by increasing renal calcitriol production that may be mediated by an increase in kidney mass [<a href="#rid118">118</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acid generated from higher animal protein intake (from the metabolism of sulfur-containing amino acids) is buffered in part by bone salts, resulting in the release of calcium from bone and an increase in urinary calcium excretion [<a href="#rid113">113-116</a>]. However, neutralizing the acid load associated with a high-protein diet does <strong>not</strong> ameliorate hypercalciuria. This was shown in a crossover study of 11 healthy adults fed a normal or high-protein diet in combination with either <a class="drug drug_general" data-topicid="10225" href="/d/drug information/10225.html" rel="external">potassium citrate</a> (an alkaline salt) or <a class="drug drug_general" data-topicid="9795" href="/d/drug information/9795.html" rel="external">potassium chloride</a> (a neutral salt) [<a href="#rid119">119</a>]. Although supplementation with potassium citrate both prevented the fall in urinary citrate excretion associated with the high-protein diet and completely neutralized the acid load, the high-protein diet still produced a significant increase in urinary calcium excretion.</p><p></p><p>The reduction in urine citrate excretion associated with higher nondairy, animal protein intake may be due to enhanced proximal citrate reabsorption [<a href="#rid113">113,114,120</a>]. This effect is induced at least in part by the fall in tubular fluid pH resulting from the acid load. The increased availability of hydrogen ions will convert the trivalent citrate anion into the divalent anion, which is more easily reabsorbed via the sodium-citrate cotransporter in the luminal membrane [<a href="#rid120">120</a>]. The associated fall in intracellular pH also may contribute by increasing cell citrate utilization [<a href="#rid121">121</a>]; the ensuing reduction in cell citrate levels favors passive citrate entry from the tubular lumen into the cell.</p><p>The ratio of nondairy, animal protein intake to potassium intake, which estimates dietary net acid load, may also be important to the risk of kidney stones. In one study, a higher animal protein-to-potassium ratio was associated with a higher risk of stone formation, even after adjustment for animal protein and potassium intake [<a href="#rid107">107</a>]. (See <a class="local">'Potassium'</a> above.)</p><p class="headingAnchor" id="H1151025975"><span class="h3">Phytate</span><span class="headingEndMark"> — </span>Higher amounts of dietary phytate may lower the risk of stone formation. In a study of nearly 100,000 younger female participants in the Nurses' Health Study II, the adjusted relative risk of stone formation among those in the highest quintile of phytate intake, compared with those in the lowest, was 0.63 (95% CI 0.51-0.78) [<a href="#rid84">84</a>]. Although its mechanism of action is unclear, calcium oxalate crystal formation is strongly inhibited in vitro by phytate. The principal dietary sources of phytate in this population were cold cereal, dark bread, and beans.</p><p class="headingAnchor" id="H1145323385"><span class="h3">Sucrose</span><span class="headingEndMark"> — </span>Higher sucrose intake is associated with an increased risk of stone formation in younger and older females [<a href="#rid83">83,84</a>]. Nearly 40 years ago, Lemann showed that an oral glucose load increased urine calcium excretion [<a href="#rid122">122</a>]. Although the mechanism is unknown, higher insulin levels may lead to higher urinary calcium excretion; however, some data are contradictory [<a href="#rid123">123</a>]. Fructose intake should also be minimized, as higher fructose intake is associated with a higher risk of kidney stones [<a href="#rid124">124</a>].</p><p class="headingAnchor" id="H3013559444"><span class="h3">Vitamin C</span><span class="headingEndMark"> — </span>High-dose <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> therapy may result in increased oxalate generation as the vitamin C (ascorbic acid) is metabolized [<a href="#rid125">125,126</a>]. A study in stone formers estimated that urinary oxalate excretion increases 6 to 13 mg/day for every 1000 mg of vitamin C ingested above 500 mg/day [<a href="#rid125">125</a>]. Subsequent metabolic studies have demonstrated that the ingestion of 2000 mg/day of vitamin C significantly increases urinary oxalate excretion in a large proportion of calcium oxalate stone formers as well as normal controls [<a href="#rid127">127,128</a>]. Two observational studies in males reported an increase in stone risk related to self-reported ingestion of larger amounts of vitamin C, but there does not appear to be an increased risk in females [<a href="#rid129">129,130</a>].</p><p>Most investigators recommend limiting the intake of <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> to the recommended dietary allowance (90 mg/day) among patients with a history of calcium oxalate stones [<a href="#rid127">127,131</a>].</p><p class="headingAnchor" id="H296429094"><span class="h3">Dietary patterns</span><span class="headingEndMark"> — </span>The combination of dietary factors may also have a significant impact upon stone risk. As an example, the DASH diet is high in fruits and vegetables, moderate in low-fat dairy products, and low in animal protein. Based upon an analysis of three large cohorts, adherence to a DASH-style diet was associated with a 40 to 45 percent lower risk for incident kidney stones among males, older females, younger females, high-BMI individuals, and low-BMI individuals [<a href="#rid132">132</a>].</p><p>Another example is the Mediterranean diet, a healthy diet associated with lower risk of several conditions including cardiovascular disease and diabetes mellitus that was also found to be associated with a lower risk of kidney stones [<a href="#rid133">133,134</a>]. In the longitudinal study of three large cohorts, higher adherence to a Mediterranean dietary pattern was associated with between 13 and 41 percent lower risk of incident kidney stones independent of potential confounders [<a href="#rid134">134</a>]. Higher adherence to the Mediterranean diet was also associated with higher urinary citrate, magnesium, oxalate, phosphate, uric acid, volume, and pH, and lower urinary sodium, resulting in an overall lower supersaturation for calcium oxalate, calcium phosphate, and uric acid.</p><p>Thus, the DASH and Mediterranean diets are reasonable options in the attempt to reduce the risk of stone recurrence. One randomized trial of the DASH diet found a suggestion of a reduced risk based upon change in 24-hour urine chemistries [<a href="#rid135">135</a>], although there are no randomized trials that have examined the effectiveness on reducing risk of actual recurrent kidney stone formation.</p><p class="headingAnchor" id="H2401250329"><span class="h2">Medications</span><span class="headingEndMark"> — </span>Several drugs have been associated with an increased risk of kidney stone formation  (<a class="graphic graphic_table graphicRef131600" href="/d/graphic/131600.html" rel="external">table 2</a>). Some drugs (eg, <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>, <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a>, long-term glucocorticoids) can promote kidney stone formation by inducing metabolic abnormalities that alter the urine composition, while others (eg, <a class="drug drug_general" data-topicid="10016" href="/d/drug information/10016.html" rel="external">triamterene</a>) can crystallize in the urine and become the primary constituent of the kidney stone (see  <a class="medical medical_review" href="/d/html/7229.html" rel="external">"Crystal-induced acute kidney injury"</a>). As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Carbonic anhydrase inhibitors (<a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a>, <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>, <a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">zonisamide</a>) increase the risk of calcium oxalate and calcium phosphate stones by reducing urinary citrate and potentially raising urine calcium due to the persistent metabolic acidosis. They can also increase the risk of calcium phosphate stones by raising the urine pH. (See  <a class="medical medical_review" href="/d/html/2369.html" rel="external">"Nephrolithiasis in renal tubular acidosis", section on 'Carbonic anhydrase inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term glucocorticoids can increase the risk of calcium oxalate and calcium phosphate stones by raising urine calcium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laxatives may increase the risk of calcium oxalate stones by inducing a malabsorptive state and thereby increasing urine oxalate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loop diuretics (eg, <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a>) may increase the risk of calcium oxalate and calcium phosphate stones by raising urine calcium.</p><p></p><p>Correction of the metabolic abnormality or discontinuation of the medication may reduce the risk of stone formation from these drugs.</p><p class="headingAnchor" id="H2537532951"><span class="h1">NONMODIFIABLE RISK FACTORS</span></p><p class="headingAnchor" id="H1029760347"><span class="h2">Family history</span><span class="headingEndMark"> — </span>The relation between family history and risk of kidney stone formation was assessed in 38,000 males in the Health Professionals Follow-up Study in the United States [<a href="#rid136">136</a>]. Over an eight-year period, individuals with a positive family history had a relative risk of 2.6 of experiencing a stone as compared with those without such a history. Higher familial risk has also been noted in Italy [<a href="#rid137">137</a>].</p><p class="headingAnchor" id="H2469467112"><span class="h2">Genetic factors</span><span class="headingEndMark"> — </span>Family history data do not distinguish between genetic and environmental factors. However, there is evidence of genetic susceptibility to the development of calcium stone disease [<a href="#rid136">136,138-140</a>]. Most investigators believe that multiple genetic loci are involved, perhaps affecting calcium absorption, resorption, and excretion; oxalate absorption; and citrate absorption and excretion. Specific genes that might be involved include the calcium-sensing receptor, tight junction proteins, calcium channels in the intestine and kidney, vitamin D receptor, vitamin D 24-hydroxylase, phosphate transporters, and oxalate exchangers [<a href="#rid27">27,113,141-145</a>].</p><p>The genetic contributions of specific genes for the common forms of stone disease have not been fully identified, but a large genome-wide association study identified associations with the sodium-dependent phosphate transporter 2A (NaPi-IIa), alkaline phosphatase, claudin-14, and possibly the calcium-sensing receptor [<a href="#rid139">139</a>]. Another large study with independent confirmation found that a genome-wide polygenic risk score was associated with urinary tract stones overall and also in the absence of known clinical risk factors for kidney stone disease [<a href="#rid140">140</a>].</p><p>Further support for genetic influences undergoing nephrolithiasis was provided by a twin study from the United States [<a href="#rid87">87</a>]. Concordance rates for a history of kidney stones were compared in monozygotic and dizygotic twins among approximately 7500 male-male twin pairs. Based upon the differences in proband rates, the heritability of stone risk was calculated to be approximately 50 percent.</p><p>Much less common is Dent disease, in which an X-linked recessive defect in an outwardly rectifying chloride channel leads to hypophosphatemia and hypercalciuria. (See  <a class="medical medical_review" href="/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia", section on 'Hypophosphatemia with hypercalciuria'</a>.)</p><p class="headingAnchor" id="H2952114659"><span class="h2">Medical conditions</span><span class="headingEndMark"> — </span>A variety of medical conditions have been associated with an increased risk of stone formation [<a href="#rid146">146-153</a>]. These conditions and potential mechanisms for their association are discussed below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary hyperparathyroidism</strong> – Affected patients are more prone to have calcium phosphate stones, but calcium oxalate stones are also common. Secondary hyperparathyroidism does not increase the risk of stone formation. (See  <a class="medical medical_review" href="/d/html/2031.html" rel="external">"Primary hyperparathyroidism: Clinical manifestations", section on 'Kidney'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertension</strong> – Primary (essential) hypertension has been associated with a higher risk of calcium and uric acid stone formation [<a href="#rid146">146,154</a>]. Possible mechanisms for this increased risk include lower urinary citrate excretion [<a href="#rid155">155</a>], higher urine calcium, higher urine oxalate, higher calcium oxalate supersaturation, and higher urine uric acid supersaturation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gout</strong> – A history of gout has been associated with an increased risk of kidney stones in males [<a href="#rid147">147,148</a>]. This higher risk may be due to a persistently acidic urine (urine pH of 5 to 5.5) in these patients, which promotes the formation of uric acid stones.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diabetes mellitus</strong> – The risk in patients with diabetes may be related in part to higher urinary calcium excretion, as well as low urinary pH predisposing to uric acid nephrolithiasis [<a href="#rid156">156,157</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity</strong> – Obesity and weight gain are risk factors for kidney stones [<a href="#rid149">149,150,152,153</a>]. The mechanism of increased risk due to obesity is unknown but may be related to higher uric acid excretion and lower urinary pH [<a href="#rid158">158,159</a>]. (See  <a class="medical medical_review" href="/d/html/7378.html" rel="external">"Kidney stones in adults: Uric acid nephrolithiasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medullary sponge kidney</strong> – Among calcium stone formers, it is estimated that this disorder is present in 12 to 20 percent overall and 20 to 30 percent of females or patients under age 20 years [<a href="#rid160">160,161</a>]. It is unclear whether the anatomic changes somehow cause the metabolic disturbances (eg, high urine calcium, low urine citrate) or whether their predisposition to nephrocalcinosis (and the interstitial deposition of calcium phosphate) increases the likelihood of nephrolithiasis. (See  <a class="medical medical_review" href="/d/html/7369.html" rel="external">"Medullary sponge kidney", section on 'Kidney stones and nephrocalcinosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distal (type 1) renal tubular acidosis</strong> – The urine pH is persistently high and leads to metabolic acidosis in most patients; there is also a tendency to have medullary nephrocalcinosis. In addition to the higher urine pH, they also tend to have lower urine citrate levels, raising the risk of calcium phosphate stones. (See  <a class="medical medical_review" href="/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis"</a> and  <a class="medical medical_review" href="/d/html/2369.html" rel="external">"Nephrolithiasis in renal tubular acidosis", section on 'Distal (type 1) RTA'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory bowel disease, short gut syndrome, bowel resection, or gastrointestinal bypass surgery</strong> – These conditions can significantly increase the risk of calcium oxalate stones by increasing urinary oxalate (due to increased gastrointestinal absorption), reducing urinary citrate (due to gastrointestinal loss of alkali) and urine volume (due to increased gastrointestinal loss of fluid or limiting fluid intake due to the reduction in stomach volume). (See  <a class="medical medical_review" href="/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Extraintestinal manifestations'</a> and  <a class="medical medical_review" href="/d/html/4775.html" rel="external">"Chronic complications of the short bowel syndrome in adults", section on 'Nephrolithiasis'</a> and  <a class="medical medical_review" href="/d/html/585.html" rel="external">"Bariatric operations: Late complications with subacute presentations", section on 'Nephrolithiasis and renal failure'</a>.)</p><p></p><p class="bulletIndent1">The rate of hyperoxaluric stone formation is higher in patients who have undergone some types of bariatric surgery. In a series of 132 patients with nephrolithiasis who had undergone bariatric surgery, the average time to formation of the first stone was 3.6 years [<a href="#rid51">51</a>]. Mean oxalate excretion was 83 mg/day in these patients who underwent malabsorptive bariatric surgery (principally Roux-en-Y gastric bypass), which was significantly higher than in routine kidney stone formers or normal subjects (39 and 34 mg/day, respectively). By contrast, a study of 18 patients who underwent restrictive bariatric procedures (gastric banding or sleeve gastrectomy) and 54 patients who underwent Roux-en-Y gastric bypass showed significantly lower 24-hour urinary oxalate excretion with restrictive procedures (35 versus 61 mg), suggesting that stone risk might be lower with restrictive procedures [<a href="#rid162">162</a>]. (See  <a class="medical medical_review" href="/d/html/88536.html" rel="external">"Bariatric procedures for the management of severe obesity: Descriptions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urinary tract infection</strong> – Patients with a chronic upper urinary tract infection due to a urease-producing organism such as Proteus or Klebsiella may be at higher risk for struvite stones. (See  <a class="medical medical_review" href="/d/html/7372.html" rel="external">"Kidney stones in adults: Struvite (infection) stones"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cystinuria</strong> – Patients with cystinuria (an autosomal recessive disorder) are at risk for developing cystine stones due to the poor solubility of the excessive amount of cystine excreted in the urine. (See  <a class="medical medical_review" href="/d/html/7362.html" rel="external">"Cystinuria and cystine stones"</a>.)</p><p></p><p class="headingAnchor" id="H1964390523"><span class="h2">Other factors</span><span class="headingEndMark"> — </span>Certain environmental factors, such as warmer climate and geography [<a href="#rid163">163-165</a>], and some occupations (eg, steel workers [<a href="#rid80">80</a>], physicians that work in the operating room) have been associated with an increased risk of kidney stones. Inadequate fluid intake in these settings may be the underlying cause for stone formation.</p><p>Betel quid chewing, a common practice in Southeast Asia, has also been associated with calcium oxalate and calcium phosphate kidney stones [<a href="#rid166">166</a>].</p><p class="headingAnchor" id="H3380798826"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4417.html" rel="external">"Patient education: Kidney stones in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2465768893"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Kidney stones (nephrolithiasis) are a common problem. Approximately 19 percent of males and 9 percent of females will be diagnosed with a kidney stone by the age of 70 years. The prevalence of kidney stones varies with age, sex, race/ethnicity, and geography. (See <a class="local">'Prevalence and incidence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stone composition</strong> – Approximately 80 percent of patients with nephrolithiasis form calcium stones, most of which are composed primarily of calcium oxalate or, less often, calcium phosphate. Other stone types include uric acid stones (8 percent), cystine stones (1 to 2 percent), struvite stones (1 percent), and miscellaneous stones (&lt;1 percent). (See <a class="local">'Stone composition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modifiable risk factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Urinary factors</strong> – Certain biochemical abnormalities of the urine composition have been associated with an increased risk for kidney stone formation, including higher urine calcium, higher urine oxalate, lower urine citrate, higher urine uric acid, and lower urine volume. The urine pH contributes to the likelihood of formation of certain types of stones; an acid urine favors uric acid precipitation, whereas an alkaline urine promotes calcium phosphate stone formation. Calcium oxalate stones are not pH dependent in the physiologic range. (See <a class="local">'Urinary factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dietary factors</strong> – Dietary factors can play an important role in promoting stone formation, primarily by affecting the composition of the urine. Lower intake of fluid, calcium, potassium, and phytate and higher intake of oxalate, sodium, sucrose, fructose, <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a>, and possibly animal protein are associated with an increased risk for calcium stone formation. Higher consumption of animal protein and lower intake of fruits and vegetables increase the risk of uric acid stones by reducing urine pH and increasing generation of uric acid. Specialized diets, such as the Dietary Approaches to Stop Hypertension (DASH) and Mediterranean diets, are reasonable options in the attempt to reduce the risk of stone recurrence. (See <a class="local">'Dietary factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medications</strong> – Several drugs have been associated with an increased risk of kidney stone formation  (<a class="graphic graphic_table graphicRef131600" href="/d/graphic/131600.html" rel="external">table 2</a>). Some drugs can promote kidney stone formation by inducing metabolic abnormalities that alter the urine composition, while others can crystallize in the urine and become the primary constituent of the kidney stone. (See <a class="local">'Medications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonmodifiable risk factors</strong> – Nonmodifiable risk factors for stone formation include a family history of stone disease, genetic susceptibility, and a variety of medical conditions. (See <a class="local">'Family history'</a> above and <a class="local">'Genetic factors'</a> above and <a class="local">'Medical conditions'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Scales CD Jr, Smith AC, Hanley JM, et al. Prevalence of kidney stones in the United States. Eur Urol 2012; 62:160.</a></li><li><a class="nounderline abstract_t">Stamatelou KK, Francis ME, Jones CA, et al. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003; 63:1817.</a></li><li><a class="nounderline abstract_t">Lieske JC, Peña de la Vega LS, Slezak JM, et al. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int 2006; 69:760.</a></li><li><a class="nounderline abstract_t">Chewcharat A, Curhan G. Trends in the prevalence of kidney stones in the United States from 2007 to 2016. Urolithiasis 2021; 49:27.</a></li><li><a class="nounderline abstract_t">Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 2010; 12:e86.</a></li><li><a class="nounderline abstract_t">Soucie JM, Thun MJ, Coates RJ, et al. Demographic and geographic variability of kidney stones in the United States. Kidney Int 1994; 46:893.</a></li><li><a class="nounderline abstract_t">Elia M, Monga M, De S. Increased Nephrolithiasis Prevalence in People with Disabilities: A National Health and Nutrition Survey Analysis. Urology 2022; 163:185.</a></li><li><a class="nounderline abstract_t">Lieske JC, Rule AD, Krambeck AE, et al. Stone composition as a function of age and sex. Clin J Am Soc Nephrol 2014; 9:2141.</a></li><li><a class="nounderline abstract_t">Hiatt RA, Ettinger B, Caan B, et al. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996; 144:25.</a></li><li><a class="nounderline abstract_t">Kocvara R, Plasgura P, Petrík A, et al. A prospective study of nonmedical prophylaxis after a first kidney stone. BJU Int 1999; 84:393.</a></li><li><a class="nounderline abstract_t">Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002; 346:77.</a></li><li><a class="nounderline abstract_t">Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med 1989; 111:1006.</a></li><li><a class="nounderline abstract_t">Ferraro PM, Curhan GC, D'Addessi A, Gambaro G. Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature. J Nephrol 2017; 30:227.</a></li><li><a class="nounderline abstract_t">Gault MH, Chafe LL, Morgan JM, et al. Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones. Medicine (Baltimore) 1991; 70:345.</a></li><li><a class="nounderline abstract_t">Levy FL, Adams-Huet B, Pak CY. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 1995; 98:50.</a></li><li><a class="nounderline abstract_t">Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 2001; 59:2290.</a></li><li><a class="nounderline abstract_t">Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int 2008; 73:489.</a></li><li><a class="nounderline abstract_t">Trinchieri A, Rovera F, Nespoli R, Currò A. Clinical observations on 2086 patients with upper urinary tract stone. Arch Ital Urol Androl 1996; 68:251.</a></li><li><a class="nounderline abstract_t">Corbetta S, Baccarelli A, Aroldi A, et al. Risk factors associated to kidney stones in primary hyperparathyroidism. J Endocrinol Invest 2005; 28:122.</a></li><li><a class="nounderline abstract_t">Pak CY. Etiology and treatment of urolithiasis. Am J Kidney Dis 1991; 18:624.</a></li><li><a class="nounderline abstract_t">Frick KK, Bushinsky DA. Molecular mechanisms of primary hypercalciuria. J Am Soc Nephrol 2003; 14:1082.</a></li><li><a class="nounderline abstract_t">Sorensen MD, Eisner BH, Stone KL, et al. Impact of calcium intake and intestinal calcium absorption on kidney stones in older women: the study of osteoporotic fractures. J Urol 2012; 187:1287.</a></li><li><a class="nounderline abstract_t">Vezzoli G, Macrina L, Rubinacci A, et al. Intestinal Calcium Absorption among Hypercalciuric Patients with or without Calcium Kidney Stones. Clin J Am Soc Nephrol 2016; 11:1450.</a></li><li><a class="nounderline abstract_t">Reed BY, Heller HJ, Gitomer WL, Pak CY. Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23.3-q24. J Clin Endocrinol Metab 1999; 84:3907.</a></li><li><a class="nounderline abstract_t">Wolf MT, Zalewski I, Martin FC, et al. Mapping a new suggestive gene locus for autosomal dominant nephrolithiasis to chromosome 9q33.2-q34.2 by total genome search for linkage. Nephrol Dial Transplant 2005; 20:909.</a></li><li><a class="nounderline abstract_t">Gambaro G, Vezzoli G, Casari G, et al. Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis 2004; 44:963.</a></li><li><a class="nounderline abstract_t">Moe OW, Bonny O. Genetic hypercalciuria. J Am Soc Nephrol 2005; 16:729.</a></li><li><a class="nounderline abstract_t">Ware EB, Smith JA, Zhao W, et al. Genome-wide Association Study of 24-Hour Urinary Excretion of Calcium, Magnesium, and Uric Acid. Mayo Clin Proc Innov Qual Outcomes 2019; 3:448.</a></li><li><a class="nounderline abstract_t">Bataille P, Achard JM, Fournier A, et al. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991; 39:1193.</a></li><li><a class="nounderline abstract_t">Lemann J Jr, Worcester EM, Gray RW. Hypercalciuria and stones. Am J Kidney Dis 1991; 17:386.</a></li><li><a class="nounderline abstract_t">Adams ND, Gray RW, Lemann J Jr, Cheung HS. Effects of calcitriol administration on calcium metabolism healthy men. Kidney Int 1982; 21:90.</a></li><li><a class="nounderline abstract_t">Pietschmann F, Breslau NA, Pak CY. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 1992; 7:1383.</a></li><li><a class="nounderline abstract_t">Martini LA, Cuppari L, Colugnati FA, et al. High sodium chloride intake is associated with low bone density in calcium stone-forming patients. Clin Nephrol 2000; 54:85.</a></li><li><a class="nounderline abstract_t">Misael da Silva AM, dos Reis LM, Pereira RC, et al. Bone involvement in idiopathic hypercalciuria. Clin Nephrol 2002; 57:183.</a></li><li><a class="nounderline abstract_t">Asplin JR, Bauer KA, Kinder J, et al. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int 2003; 63:662.</a></li><li><a class="nounderline abstract_t">Ferraro PM, Taylor EN, Gambaro G, Curhan GC. Vitamin D Intake and the Risk of Incident Kidney Stones. J Urol 2017; 197:405.</a></li><li><a class="nounderline abstract_t">Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354:669.</a></li><li><a class="nounderline abstract_t">Lau YK, Wasserstein A, Westby GR, et al. Proximal tubular defects in idiopathic hypercalciuria: resistance to phosphate administration. Miner Electrolyte Metab 1982; 7:237.</a></li><li><a class="nounderline abstract_t">Gambaro G, Petrarulo M, Nardelotto A, et al. Erythrocyte transmembrane flux and renal clearance of oxalate in idiopathic calcium nephrolithiasis. Kidney Int 1995; 48:1549.</a></li><li><a class="nounderline abstract_t">Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001; 59:270.</a></li><li><a class="nounderline abstract_t">Smith LH. Diet and hyperoxaluria in the syndrome of idiopathic calcium oxalate urolithiasis. Am J Kidney Dis 1991; 17:370.</a></li><li><a class="nounderline abstract_t">Robijn S, Hoppe B, Vervaet BA, et al. Hyperoxaluria: a gut-kidney axis? Kidney Int 2011; 80:1146.</a></li><li><a class="nounderline abstract_t">Taylor EN, Curhan GC. Oxalate intake and the risk for nephrolithiasis. J Am Soc Nephrol 2007; 18:2198.</a></li><li><a class="nounderline abstract_t">Voss S, Hesse A, Zimmermann DJ, et al. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test. J Urol 2006; 175:1711.</a></li><li><a class="nounderline abstract_t">Parks JH, Worcester EM, O'Connor RC, Coe FL. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 2003; 63:255.</a></li><li><a class="nounderline abstract_t">Annuk M, Backman U, Holmgren K, Vessby B. Urinary calculi and jejunoileal bypass operation. A long-term follow-up. Scand J Urol Nephrol 1998; 32:177.</a></li><li><a class="nounderline abstract_t">Hassan I, Juncos LA, Milliner DS, et al. Chronic renal failure secondary to oxalate nephropathy: a preventable complication after jejunoileal bypass. Mayo Clin Proc 2001; 76:758.</a></li><li><a class="nounderline abstract_t">Dhar NB, Grundfest S, Jones JS, Streem SB. Jejunoileal bypass reversal: effect on renal function, metabolic parameters and stone formation. J Urol 2005; 174:1844.</a></li><li><a class="nounderline abstract_t">McConnell N, Campbell S, Gillanders I, et al. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int 2002; 89:835.</a></li><li><a class="nounderline abstract_t">Terribile M, Capuano M, Cangiano G, et al. Factors increasing the risk for stone formation in adult patients with cystic fibrosis. Nephrol Dial Transplant 2006; 21:1870.</a></li><li><a class="nounderline abstract_t">Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol 2007; 177:565.</a></li><li><a class="nounderline abstract_t">Sinha MK, Collazo-Clavell ML, Rule A, et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int 2007; 72:100.</a></li><li><a class="nounderline abstract_t">Williams HE. Oxalic acid and the hyperoxaluric syndromes. Kidney Int 1978; 13:410.</a></li><li><a class="nounderline abstract_t">Kathpalia SC, Favus MJ, Coe FL. Evidence for size and charge permselectivity of rat ascending colon. Effects of ricinoleate and bile salts on oxalic acid and neutral sugar transport. J Clin Invest 1984; 74:805.</a></li><li><a class="nounderline abstract_t">Obialo CI, Clayman RV, Matts JP, et al. Pathogenesis of nephrolithiasis post-partial ileal bypass surgery: case-control study. The POSCH Group. Kidney Int 1991; 39:1249.</a></li><li><a class="nounderline abstract_t">Witting C, Langman CB, Assimos D, et al. Pathophysiology and Treatment of Enteric Hyperoxaluria. Clin J Am Soc Nephrol 2021; 16:487.</a></li><li><a class="nounderline abstract_t">Hoppe B, von Unruh GE, Blank G, et al. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis. Am J Kidney Dis 2005; 46:440.</a></li><li><a class="nounderline abstract_t">Sidhu H, Hoppe B, Hesse A, et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet 1998; 352:1026.</a></li><li><a class="nounderline abstract_t">Mittal RD, Kumar R, Mittal B, et al. Stone composition, metabolic profile and the presence of the gut-inhabiting bacterium Oxalobacter formigenes as risk factors for renal stone formation. Med Princ Pract 2003; 12:208.</a></li><li><a class="nounderline abstract_t">Duncan SH, Richardson AJ, Kaul P, et al. Oxalobacter formigenes and its potential role in human health. Appl Environ Microbiol 2002; 68:3841.</a></li><li><a class="nounderline abstract_t">Goldfarb DS. Microorganisms and calcium oxalate stone disease. Nephron Physiol 2004; 98:p48.</a></li><li><a class="nounderline abstract_t">Hatch M, Cornelius J, Allison M, et al. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006; 69:691.</a></li><li><a class="nounderline abstract_t">Kaufman DW, Kelly JP, Curhan GC, et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 2008; 19:1197.</a></li><li><a class="nounderline abstract_t">Barnett C, Nazzal L, Goldfarb DS, Blaser MJ. The Presence of Oxalobacter formigenes in the Microbiome of Healthy Young Adults. J Urol 2016; 195:499.</a></li><li><a class="nounderline abstract_t">Jiang Z, Asplin JR, Evan AP, et al. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet 2006; 38:474.</a></li><li><a class="nounderline abstract_t">Parks JH, Coe FL. A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 1986; 30:85.</a></li><li><a class="nounderline abstract_t">Rudman D, Kutner MH, Redd SC 2nd, et al. Hypocitraturia in calcium nephrolithiasis. J Clin Endocrinol Metab 1982; 55:1052.</a></li><li><a class="nounderline abstract_t">Asplin JR, Parks JH, Chen MS, et al. Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int 1999; 56:1505.</a></li><li><a class="nounderline abstract_t">Asplin JR, Parks JH, Nakagawa Y, Coe FL. Reduced crystallization inhibition by urine from women with nephrolithiasis. Kidney Int 2002; 61:1821.</a></li><li><a class="nounderline abstract_t">Wesson JA, Johnson RJ, Mazzali M, et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 2003; 14:139.</a></li><li><a class="nounderline abstract_t">Kok DJ, Papapoulos SE, Bijvoet OL. Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int 1990; 37:51.</a></li><li><a class="nounderline abstract_t">Mandel EI, Taylor EN, Curhan GC. Dietary and lifestyle factors and medical conditions associated with urinary citrate excretion. Clin J Am Soc Nephrol 2013; 8:901.</a></li><li><a class="nounderline abstract_t">Domrongkitchaiporn S, Stitchantrakul W, Kochakarn W. Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion. Am J Kidney Dis 2006; 48:546.</a></li><li><a class="nounderline abstract_t">Donnelly S, Kamel KS, Vasuvattakul S, et al. Might distal renal tubular acidosis be a proximal tubular cell disorder? Am J Kidney Dis 1992; 19:272.</a></li><li><a class="nounderline abstract_t">Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327:1141.</a></li><li><a class="nounderline abstract_t">Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986; 315:1386.</a></li><li><a class="nounderline abstract_t">Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol 2014; 192:316.</a></li><li><a class="nounderline abstract_t">Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996; 155:839.</a></li><li><a class="nounderline abstract_t">Ferraro PM, Taylor EN, Gambaro G, Curhan GC. Dietary and Lifestyle Risk Factors Associated with Incident Kidney Stones in Men and Women. J Urol 2017; 198:858.</a></li><li><a class="nounderline abstract_t">Atan L, Andreoni C, Ortiz V, et al. High kidney stone risk in men working in steel industry at hot temperatures. Urology 2005; 65:858.</a></li><li><a class="nounderline abstract_t">Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993; 328:833.</a></li><li><a class="nounderline abstract_t">Taylor EN, Stampfer MJ, Curhan GC. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 2004; 15:3225.</a></li><li><a class="nounderline abstract_t">Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997; 126:497.</a></li><li><a class="nounderline abstract_t">Curhan GC, Willett WC, Knight EL, Stampfer MJ. Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II. Arch Intern Med 2004; 164:885.</a></li><li><a class="nounderline abstract_t">Ferraro PM, Taylor EN, Gambaro G, Curhan GC. Soda and other beverages and the risk of kidney stones. Clin J Am Soc Nephrol 2013; 8:1389.</a></li><li><a class="nounderline abstract_t">Brinkley LJ, Gregory J, Pak CY. A further study of oxalate bioavailability in foods. J Urol 1990; 144:94.</a></li><li><a class="nounderline abstract_t">Goldfarb DS, Fischer ME, Keich Y, Goldberg J. A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int 2005; 67:1053.</a></li><li><a class="nounderline abstract_t">Littlejohns TJ, Neal NL, Bradbury KE, et al. Fluid Intake and Dietary Factors and the Risk of Incident Kidney Stones in UK Biobank: A Population-based Prospective Cohort Study. Eur Urol Focus 2020; 6:752.</a></li><li><a class="nounderline abstract_t">Hirvonen T, Pietinen P, Virtanen M, et al. Nutrient intake and use of beverages and the risk of kidney stones among male smokers. Am J Epidemiol 1999; 150:187.</a></li><li><a class="nounderline abstract_t">Helderman JH, Vestal RE, Rowe JW, et al. The response of arginine vasopressin to intravenous ethanol and hypertonic saline in man: the impact of aging. J Gerontol 1978; 33:39.</a></li><li><a class="nounderline abstract_t">Eisenhofer G, Johnson RH. Effect of ethanol ingestion on plasma vasopressin and water balance in humans. Am J Physiol 1982; 242:R522.</a></li><li><a class="nounderline abstract_t">Hönow R, Laube N, Schneider A, et al. Influence of grapefruit-, orange- and apple-juice consumption on urinary variables and risk of crystallization. Br J Nutr 2003; 90:295.</a></li><li><a class="nounderline abstract_t">Wabner CL, Pak CY. Effect of orange juice consumption on urinary stone risk factors. J Urol 1993; 149:1405.</a></li><li><a class="nounderline abstract_t">Odvina CV. Comparative value of orange juice versus lemonade in reducing stone-forming risk. Clin J Am Soc Nephrol 2006; 1:1269.</a></li><li><a class="nounderline abstract_t">Gettman MT, Ogan K, Brinkley LJ, et al. Effect of cranberry juice consumption on urinary stone risk factors. J Urol 2005; 174:590.</a></li><li><a class="nounderline abstract_t">Kessler T, Jansen B, Hesse A. Effect of blackcurrant-, cranberry- and plum juice consumption on risk factors associated with kidney stone formation. Eur J Clin Nutr 2002; 56:1020.</a></li><li><a class="nounderline abstract_t">McHarg T, Rodgers A, Charlton K. Influence of cranberry juice on the urinary risk factors for calcium oxalate kidney stone formation. BJU Int 2003; 92:765.</a></li><li><a class="nounderline abstract_t">Lemann J Jr. Composition of the diet and calcium kidney stones. N Engl J Med 1993; 328:880.</a></li><li><a class="nounderline abstract_t">Taylor EN, Curhan GC. Dietary calcium from dairy and nondairy sources, and risk of symptomatic kidney stones. J Urol 2013; 190:1255.</a></li><li><a class="nounderline abstract_t">Pak CY, Odvina CV, Pearle MS, et al. Effect of dietary modification on urinary stone risk factors. Kidney Int 2005; 68:2264.</a></li><li><a class="nounderline abstract_t">Mitchell T, Kumar P, Reddy T, et al. Dietary oxalate and kidney stone formation. Am J Physiol Renal Physiol 2019; 316:F409.</a></li><li><a class="nounderline abstract_t">Siener R, Hönow R, Voss S, et al. Oxalate content of cereals and cereal products. J Agric Food Chem 2006; 54:3008.</a></li><li><a class="nounderline abstract_t">Siener R, Ebert D, Nicolay C, Hesse A. Dietary risk factors for hyperoxaluria in calcium oxalate stone formers. Kidney Int 2003; 63:1037.</a></li><li><a class="nounderline abstract_t">Lieske JC, Tremaine WJ, De Simone C, et al. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int 2010; 78:1178.</a></li><li><a class="nounderline abstract_t">Hess B, Jost C, Zipperle L, et al. High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 1998; 13:2241.</a></li><li><a class="nounderline abstract_t">Liebman M, Costa G. Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads. J Urol 2000; 163:1565.</a></li><li><a class="nounderline abstract_t">Ferraro PM, Mandel EI, Curhan GC, et al. Dietary Protein and Potassium, Diet-Dependent Net Acid Load, and Risk of Incident Kidney Stones. Clin J Am Soc Nephrol 2016; 11:1834.</a></li><li><a class="nounderline abstract_t">Lemann J Jr, Pleuss JA, Gray RW, Hoffmann RG. Potassium administration reduces and potassium deprivation increases urinary calcium excretion in healthy adults [corrected]. Kidney Int 1991; 39:973.</a></li><li><a class="nounderline abstract_t">Friedman PA, Gesek FA. Calcium transport in renal epithelial cells. Am J Physiol 1993; 264:F181.</a></li><li><a class="nounderline abstract_t">Muldowney FP, Freaney R, Moloney MF. Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 1982; 22:292.</a></li><li><a class="nounderline abstract_t">Sakhaee K, Harvey JA, Padalino PK, et al. The potential role of salt abuse on the risk for kidney stone formation. J Urol 1993; 150:310.</a></li><li><a class="nounderline abstract_t">Sorensen MD, Kahn AJ, Reiner AP, et al. Impact of nutritional factors on incident kidney stone formation: a report from the WHI OS. J Urol 2012; 187:1645.</a></li><li><a class="nounderline abstract_t">Reddy ST, Wang CY, Sakhaee K, et al. Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. Am J Kidney Dis 2002; 40:265.</a></li><li><a class="nounderline abstract_t">Kok DJ, Iestra JA, Doorenbos CJ, Papapoulos SE. The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men. J Clin Endocrinol Metab 1990; 71:861.</a></li><li><a class="nounderline abstract_t">Breslau NA, Brinkley L, Hill KD, Pak CY. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 1988; 66:140.</a></li><li><a class="nounderline abstract_t">Amanzadeh J, Gitomer WL, Zerwekh JE, et al. Effect of high protein diet on stone-forming propensity and bone loss in rats. Kidney Int 2003; 64:2142.</a></li><li><a class="nounderline abstract_t">Shu X, Calvert JK, Cai H, et al. Plant and Animal Protein Intake and Risk of Incident Kidney Stones: Results from the Shanghai Men's and Women's Health Studies. J Urol 2019; 202:1217.</a></li><li><a class="nounderline abstract_t">Hess B, Ackermann D, Essig M, et al. Renal mass and serum calcitriol in male idiopathic calcium renal stone formers: role of protein intake. J Clin Endocrinol Metab 1995; 80:1916.</a></li><li><a class="nounderline abstract_t">Maalouf NM, Moe OW, Adams-Huet B, Sakhaee K. Hypercalciuria associated with high dietary protein intake is not due to acid load. J Clin Endocrinol Metab 2011; 96:3733.</a></li><li><a class="nounderline abstract_t">Hamm LL. Renal handling of citrate. Kidney Int 1990; 38:728.</a></li><li><a class="nounderline abstract_t">Melnick JZ, Srere PA, Elshourbagy NA, et al. Adenosine triphosphate citrate lyase mediates hypocitraturia in rats. J Clin Invest 1996; 98:2381.</a></li><li><a class="nounderline abstract_t">Lemann J Jr, Piering WF, Lennon EJ. Possible role of carbohydrate-induced calciuria in calcium oxalate kidney-stone formation. N Engl J Med 1969; 280:232.</a></li><li><a class="nounderline abstract_t">Abate N, Chandalia M, Cabo-Chan AV Jr, et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004; 65:386.</a></li><li><a class="nounderline abstract_t">Taylor EN, Curhan GC. Fructose consumption and the risk of kidney stones. Kidney Int 2008; 73:207.</a></li><li><a class="nounderline abstract_t">Urivetzky M, Kessaris D, Smith AD. Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis. J Urol 1992; 147:1215.</a></li><li><a class="nounderline abstract_t">Baxmann AC, De O G Mendonça C, Heilberg IP. Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients. Kidney Int 2003; 63:1066.</a></li><li><a class="nounderline abstract_t">Traxer O, Huet B, Poindexter J, et al. Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 2003; 170:397.</a></li><li><a class="nounderline abstract_t">Massey LK, Liebman M, Kynast-Gales SA. Ascorbate increases human oxaluria and kidney stone risk. J Nutr 2005; 135:1673.</a></li><li><a class="nounderline abstract_t">Thomas LD, Elinder CG, Tiselius HG, et al. Ascorbic acid supplements and kidney stone incidence among men: a prospective study. JAMA Intern Med 2013; 173:386.</a></li><li><a class="nounderline abstract_t">Ferraro PM, Curhan GC, Gambaro G, Taylor EN. Total, Dietary, and Supplemental Vitamin C Intake and Risk of Incident Kidney Stones. Am J Kidney Dis 2016; 67:400.</a></li><li><a class="nounderline abstract_t">Chai W, Liebman M, Kynast-Gales S, Massey L. Oxalate absorption and endogenous oxalate synthesis from ascorbate in calcium oxalate stone formers and non-stone formers. Am J Kidney Dis 2004; 44:1060.</a></li><li><a class="nounderline abstract_t">Taylor EN, Fung TT, Curhan GC. DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol 2009; 20:2253.</a></li><li><a class="nounderline abstract_t">Leone A, Fernández-Montero A, de la Fuente-Arrillaga C, et al. Adherence to the Mediterranean Dietary Pattern and Incidence of Nephrolithiasis in the Seguimiento Universidad de Navarra Follow-up (SUN) Cohort. Am J Kidney Dis 2017; 70:778.</a></li><li><a class="nounderline abstract_t">Rodriguez A, Curhan GC, Gambaro G, et al. Mediterranean diet adherence and risk of incident kidney stones. Am J Clin Nutr 2020; 111:1100.</a></li><li><a class="nounderline abstract_t">Noori N, Honarkar E, Goldfarb DS, et al. Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets. Am J Kidney Dis 2014; 63:456.</a></li><li><a class="nounderline abstract_t">Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Family history and risk of kidney stones. J Am Soc Nephrol 1997; 8:1568.</a></li><li><a class="nounderline abstract_t">Serio A, Fraioli A. Epidemiology of nephrolithiasis. Nephron 1999; 81 Suppl 1:26.</a></li><li><a class="nounderline abstract_t">Sayer JA. Progress in Understanding the Genetics of Calcium-Containing Nephrolithiasis. J Am Soc Nephrol 2017; 28:748.</a></li><li><a class="nounderline abstract_t">Oddsson A, Sulem P, Helgason H, et al. Common and rare variants associated with kidney stones and biochemical traits. Nat Commun 2015; 6:7975.</a></li><li><a class="nounderline abstract_t">Paranjpe I, Tsao N, Judy R, et al. Derivation and validation of genome-wide polygenic score for urinary tract stone diagnosis. Kidney Int 2020; 98:1323.</a></li><li><a class="nounderline abstract_t">Goodman HO, Holmes RP, Assimos DG. Genetic factors in calcium oxalate stone disease. J Urol 1995; 153:301.</a></li><li><a class="nounderline abstract_t">Tencza AL, Ichikawa S, Dang A, et al. Hypophosphatemic rickets with hypercalciuria due to mutation in SLC34A3/type IIc sodium-phosphate cotransporter: presentation as hypercalciuria and nephrolithiasis. J Clin Endocrinol Metab 2009; 94:4433.</a></li><li><a class="nounderline abstract_t">Thorleifsson G, Holm H, Edvardsson V, et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 2009; 41:926.</a></li><li><a class="nounderline abstract_t">Dinour D, Beckerman P, Ganon L, et al. Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. J Urol 2013; 190:552.</a></li><li><a class="nounderline abstract_t">Nesterova G, Malicdan MC, Yasuda K, et al. 1,25-(OH)2D-24 Hydroxylase (CYP24A1) Deficiency as a Cause of Nephrolithiasis. Clin J Am Soc Nephrol 2013; 8:649.</a></li><li><a class="nounderline abstract_t">Ando R, Nagaya T, Suzuki S, et al. Kidney stone formation is positively associated with conventional risk factors for coronary heart disease in Japanese men. J Urol 2013; 189:1340.</a></li><li><a class="nounderline abstract_t">Kramer HJ, Choi HK, Atkinson K, et al. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int 2003; 64:1022.</a></li><li><a class="nounderline abstract_t">Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002; 40:37.</a></li><li><a class="nounderline abstract_t">Curhan GC, Willett WC, Rimm EB, et al. Body size and risk of kidney stones. J Am Soc Nephrol 1998; 9:1645.</a></li><li><a class="nounderline abstract_t">Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005; 293:455.</a></li><li><a class="nounderline abstract_t">Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 2005; 68:1230.</a></li><li><a class="nounderline abstract_t">Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urol Res 2006; 34:193.</a></li><li><a class="nounderline abstract_t">Sarica K, Altay B, Erturhan S. Effect of being overweight on stone-forming risk factors. Urology 2008; 71:771.</a></li><li><a class="nounderline abstract_t">Borghi L, Meschi T, Guerra A, et al. Essential arterial hypertension and stone disease. Kidney Int 1999; 55:2397.</a></li><li><a class="nounderline abstract_t">Taylor EN, Mount DB, Forman JP, Curhan GC. Association of prevalent hypertension with 24-hour urinary excretion of calcium, citrate, and other factors. Am J Kidney Dis 2006; 47:780.</a></li><li><a class="nounderline abstract_t">Cameron MA, Maalouf NM, Adams-Huet B, et al. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol 2006; 17:1422.</a></li><li><a class="nounderline abstract_t">Lee CT, Lien YH, Lai LW, et al. Increased renal calcium and magnesium transporter abundance in streptozotocin-induced diabetes mellitus. Kidney Int 2006; 69:1786.</a></li><li><a class="nounderline abstract_t">Maalouf NM, Sakhaee K, Parks JH, et al. Association of urinary pH with body weight in nephrolithiasis. Kidney Int 2004; 65:1422.</a></li><li><a class="nounderline abstract_t">Taylor EN, Curhan GC. Body size and 24-hour urine composition. Am J Kidney Dis 2006; 48:905.</a></li><li><a class="nounderline abstract_t">Yagisawa T, Kobayashi C, Hayashi T, et al. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney. Am J Kidney Dis 2001; 37:1140.</a></li><li><a class="nounderline abstract_t">Parks JH, Coe FL, Strauss AL. Calcium nephrolithiasis and medullary sponge kidney in women. N Engl J Med 1982; 306:1088.</a></li><li><a class="nounderline abstract_t">Semins MJ, Asplin JR, Steele K, et al. The effect of restrictive bariatric surgery on urinary stone risk factors. Urology 2010; 76:826.</a></li><li><a class="nounderline abstract_t">Brikowski TH, Lotan Y, Pearle MS. Climate-related increase in the prevalence of urolithiasis in the United States. Proc Natl Acad Sci U S A 2008; 105:9841.</a></li><li><a class="nounderline abstract_t">Soucie JM, Coates RJ, McClellan W, et al. Relation between geographic variability in kidney stones prevalence and risk factors for stones. Am J Epidemiol 1996; 143:487.</a></li><li><a class="nounderline abstract_t">Maline GE, Goldfarb DS. Climate change and kidney stones. Curr Opin Nephrol Hypertens 2024; 33:89.</a></li><li><a class="nounderline abstract_t">Allen SE, Singh S, Robertson WG. The increased risk of urinary stone disease in betel quid chewers. Urol Res 2006; 34:239.</a></li></ol></div><div id="topicVersionRevision">Topic 7375 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22498635" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevalence of kidney stones in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12675858" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Time trends in reported prevalence of kidney stones in the United States: 1976-1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16518332" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Renal stone epidemiology in Rochester, Minnesota: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32870387" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Trends in the prevalence of kidney stones in the United States from 2007 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20811557" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Kidney stones: a global picture of prevalence, incidence, and associated risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7996811" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Demographic and geographic variability of kidney stones in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34619156" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Increased Nephrolithiasis Prevalence in People with Disabilities: A National Health and Nutrition Survey Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25278549" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Stone composition as a function of age and sex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8659482" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468751" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A prospective study of nonmedical prophylaxis after a first kidney stone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11784873" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2688503" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The first kidney stone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26969574" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1956278" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7825619" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11380833" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Twenty-four-hour urine chemistries and the risk of kidney stones among women and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18059457" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : 24-h uric acid excretion and the risk of kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8936717" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical observations on 2086 patients with upper urinary tract stone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15887857" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk factors associated to kidney stones in primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1962646" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Etiology and treatment of urolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660344" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Molecular mechanisms of primary hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22341269" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Impact of calcium intake and intestinal calcium absorption on kidney stones in older women: the study of osteoporotic fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27284011" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Intestinal Calcium Absorption among Hypercalciuric Patients with or without Calcium Kidney Stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10566627" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23.3-q24.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741201" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mapping a new suggestive gene locus for autosomal dominant nephrolithiasis to chromosome 9q33.2-q34.2 by total genome search for linkage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558518" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15689405" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Genetic hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31993563" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Genome-wide Association Study of 24-Hour Urinary Excretion of Calcium, Magnesium, and Uric Acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1895673" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2008904" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hypercalciuria and stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6896223" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of calcitriol administration on calcium metabolism healthy men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1481724" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Reduced vertebral bone density in hypercalciuric nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10968683" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High sodium chloride intake is associated with low bone density in calcium stone-forming patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11926201" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bone involvement in idiopathic hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631132" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27545576" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Vitamin D Intake and the Risk of Incident Kidney Stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16481635" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Calcium plus vitamin D supplementation and the risk of fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7169988" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Proximal tubular defects in idiopathic hypercalciuria: resistance to phosphate administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8544412" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Erythrocyte transmembrane flux and renal clearance of oxalate in idiopathic calcium nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11135080" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Contribution of dietary oxalate to urinary oxalate excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2008901" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Diet and hyperoxaluria in the syndrome of idiopathic calcium oxalate urolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21866092" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hyperoxaluria: a gut-kidney axis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538185" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Oxalate intake and the risk for nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16600737" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472791" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Urine stone risk factors in nephrolithiasis patients with and without bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9689695" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Urinary calculi and jejunoileal bypass operation. A long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11444411" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Chronic renal failure secondary to oxalate nephropathy: a preventable complication after jejunoileal bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16217311" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Jejunoileal bypass reversal: effect on renal function, metabolic parameters and stone formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12010224" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Risk factors for developing renal stones in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16595587" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Factors increasing the risk for stone formation in adult patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222634" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hyperoxaluria in kidney stone formers treated with modern bariatric surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17377509" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/351269" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Oxalic acid and the hyperoxaluric syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6432849" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Evidence for size and charge permselectivity of rat ascending colon. Effects of ricinoleate and bile salts on oxalic acid and neutral sugar transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1895677" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pathogenesis of nephrolithiasis post-partial ileal bypass surgery: case-control study. The POSCH Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32900691" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pathophysiology and Treatment of Enteric Hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129205" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9759746" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12966191" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Stone composition, metabolic profile and the presence of the gut-inhabiting bacterium Oxalobacter formigenes as risk factors for renal stone formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12147479" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Oxalobacter formigenes and its potential role in human health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15499215" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Microorganisms and calcium oxalate stone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16518326" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18322162" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26292041" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The Presence of Oxalobacter formigenes in the Microbiome of Healthy Young Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16532010" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3747347" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A urinary calcium-citrate index for the evaluation of nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7130336" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hypocitraturia in calcium nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10504502" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Reduced crystallization inhibition by urine from men with nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11967033" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Reduced crystallization inhibition by urine from women with nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12506146" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2299809" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Crystal agglomeration is a major element in calcium oxalate urinary stone formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23449767" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Dietary and lifestyle factors and medical conditions associated with urinary citrate excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16997050" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1553972" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Might distal renal tubular acidosis be a proximal tubular cell disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1528210" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The pathogenesis and treatment of kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3534570" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Randomized trial of allopurinol in the prevention of calcium oxalate calculi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24857648" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Medical management of kidney stones: AUA guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8583588" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28365271" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Dietary and Lifestyle Risk Factors Associated with Incident Kidney Stones in Men and Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15882711" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : High kidney stone risk in men working in steel industry at hot temperatures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8441427" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579526" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9092314" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15111375" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23676355" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Soda and other beverages and the risk of kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2359186" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A further study of oxalate bioavailability in foods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15698445" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31085062" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Fluid Intake and Dietary Factors and the Risk of Incident Kidney Stones in UK Biobank: A Population-based Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10412964" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Nutrient intake and use of beverages and the risk of kidney stones among male smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/618965" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The response of arginine vasopressin to intravenous ethanol and hypertonic saline in man: the impact of aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7081477" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effect of ethanol ingestion on plasma vasopressin and water balance in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12908889" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Influence of grapefruit-, orange- and apple-juice consumption on urinary variables and risk of crystallization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8501777" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Effect of orange juice consumption on urinary stone risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699358" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Comparative value of orange juice versus lemonade in reducing stone-forming risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16006907" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effect of cranberry juice consumption on urinary stone risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373623" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Effect of blackcurrant-, cranberry- and plum juice consumption on risk factors associated with kidney stone formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616463" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Influence of cranberry juice on the urinary risk factors for calcium oxalate kidney stone formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8441433" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Composition of the diet and calcium kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23535174" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Dietary calcium from dairy and nondairy sources, and risk of symptomatic kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16221228" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Effect of dietary modification on urinary stone risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30566003" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Dietary oxalate and kidney stone formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16608223" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Oxalate content of cereals and cereal products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631085" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Dietary risk factors for hyperoxaluria in calcium oxalate stone formers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736987" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9761503" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10751889" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27445166" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Dietary Protein and Potassium, Diet-Dependent Net Acid Load, and Risk of Incident Kidney Stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1648646" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Potassium administration reduces and potassium deprivation increases urinary calcium excretion in healthy adults [corrected].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8447431" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Calcium transport in renal epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7176331" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Importance of dietary sodium in the hypercalciuria syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8326549" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The potential role of salt abuse on the risk for kidney stone formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22425103" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Impact of nutritional factors on incident kidney stone formation: a report from the WHI OS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12148098" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2401715" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2826524" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14633136" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Effect of high protein diet on stone-forming propensity and bone loss in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31430246" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Plant and Animal Protein Intake and Risk of Incident Kidney Stones: Results from the Shanghai Men's and Women's Health Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7775641" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Renal mass and serum calcitriol in male idiopathic calcium renal stone formers: role of protein intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21976719" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Hypercalciuria associated with high dietary protein intake is not due to acid load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2232510" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Renal handling of citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8941657" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Adenosine triphosphate citrate lyase mediates hypocitraturia in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5818178" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Possible role of carbohydrate-induced calciuria in calcium oxalate kidney-stone formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717908" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17928824" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Fructose consumption and the risk of kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1569652" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631089" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12853784" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Effect of ascorbic acid consumption on urinary stone risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15987848" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Ascorbate increases human oxaluria and kidney stone risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23381591" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Ascorbic acid supplements and kidney stone incidence among men: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26463139" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Total, Dietary, and Supplemental Vitamin C Intake and Risk of Incident Kidney Stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558527" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Oxalate absorption and endogenous oxalate synthesis from ascorbate in calcium oxalate stone formers and non-stone formers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19679672" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : DASH-style diet associates with reduced risk for kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28838765" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Adherence to the Mediterranean Dietary Pattern and Incidence of Nephrolithiasis in the Seguimiento Universidad de Navarra Follow-up (SUN) Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32271884" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Mediterranean diet adherence and risk of incident kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24560157" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9335385" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Family history and risk of kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9873211" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Epidemiology of nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27932479" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Progress in Understanding the Genetics of Calcium-Containing Nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26272126" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Common and rare variants associated with kidney stones and biochemical traits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32540406" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Derivation and validation of genome-wide polygenic score for urinary tract stone diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7815569" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Genetic factors in calcium oxalate stone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820004" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Hypophosphatemic rickets with hypercalciuria due to mutation in SLC34A3/type IIc sodium-phosphate cotransporter: presentation as hypercalciuria and nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19561606" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23470222" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23293122" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : 1,25-(OH)2D-24 Hydroxylase (CYP24A1) Deficiency as a Cause of Nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23159273" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Kidney stone formation is positively associated with conventional risk factors for coronary heart disease in Japanese men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12911552" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12087559" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9727373" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Body size and risk of kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15671430" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Obesity, weight gain, and the risk of kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16105055" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Diabetes mellitus and the risk of nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16474948" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Influence of body size on urinary stone composition in men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18336885" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Effect of being overweight on stone-forming risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10354288" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Essential arterial hypertension and stone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16632016" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Association of prevalent hypertension with 24-hour urinary excretion of calcium, citrate, and other factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16597681" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16557223" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Increased renal calcium and magnesium transporter abundance in streptozotocin-induced diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086484" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Association of urinary pH with body weight in nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17162145" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Body size and 24-hour urine composition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11382681" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7070404" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Calcium nephrolithiasis and medullary sponge kidney in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20381135" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : The effect of restrictive bariatric surgery on urinary stone risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626008" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Climate-related increase in the prevalence of urolithiasis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8610664" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Relation between geographic variability in kidney stones prevalence and risk factors for stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37725125" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Climate change and kidney stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534642" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : The increased risk of urinary stone disease in betel quid chewers.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
